09.10.2012 • News • Solvay • Joint Ventures • chemical industry

Solvay, Sibur Form JV to Produce Surfactants and Oilfield Process Chemicals

Solvay and Russian petrochemical company Sibur have signed an agreement to establish Ruspav, a 50/50 joint venture for the production of surfactants and oilfield process chemicals in Dzerzhinsk, Russia.

The agreement was signed in presence of the Minister of Energy of the Russian Federation, Alexander Novak, during the 26th Gastech Conference in London today by Dmitry Konov, CEO of Sibur, and Emmanuel Butstraen, Head of Solvay's Global Business Unit Novecare.

Ruspav will be located near Sibur's petrochemicals operations, 400km east of Moscow, and is expected to be operational in 2015. Demand for surfactants in the CIS is growing at more than six percent annually. The surfactants are used mainly in home & personal care products, oil & gas as well as in other industries.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.